Real-world check of Rexulti for schizophrenia and depression
Treatments studied
Part of Mental health clinical trials.
This study looks at how well brexpiprazole (Rexulti) works in everyday treatment, and how people feel and function over time. You may be eligible if you’re newly started on Rexulti and have a qualifying mental health diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old when you enroll
- Be able to read and communicate in English and/or Chinese
- Be able to understand the study and give informed consent
- Have a diagnosis that matches schizophrenia or related psychotic disorders (DSM-5 or ICD-10)
- Be taking brexpiprazole for less than 4 weeks at the time of recruitment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying how a medication called REXULTI works in patients with Alzheimer's disease who have symptoms like excessive activity, aggression, or mood swings. It aims to see if the drug helps manage these behaviors.
This Phase 3 study tests whether brexpiprazole can help treat bipolar depression that has not responded to previous treatments. It compares the study medicine to a placebo (inactive pill) for people with bipolar I or II depression.
This trial tests a new long-acting injection of brexpiprazole, an antipsychotic that may help control schizophrenia symptoms. The study will see how the injection is absorbed, its safety, and how well people tolerate it, potentially offering a longer-lasting treatment option.
This study tests an injectable form of brexpiprazole that stays in the body for a long time. It aims to see if the shot is safe and tolerable for healthy volunteers and people with schizophrenia, and how the body processes it.
This Phase 3 study tests whether a once-weekly brexpiprazole medicine can help people whose schizophrenia is currently flaring up and who need hospital-level care. It compares care for acute relapse using a longer-lasting (weekly) form of brexpiprazole.
This Phase 4 study tests an “optimized” medication approach for adults with major depressive disorder (unipolar depression) based on how you respond over time. It may help your care team choose treatments more effectively and reduce trial-and-error.
Hear when a new Psychosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.